본문으로 건너뛰기
← 뒤로

A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations.

ESMO open 2026 Vol.11(1) p. 105932

Ródon J, Arkenau HT, Funchain P, Hervieu A, Anthony K, Chawla SP, Laetsch TW, Murciano-Goroff YR, Singer CF, He Y, Mina M, Wacheck V, Delaloge S

📝 환자 설명용 한 줄

[BACKGROUND] Protein kinase B (AKT)-directed therapies offer promise for patients with cancers harboring germline and somatic phosphatase and tensin homolog (PTEN) mutations.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 16

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Ródon J, Arkenau HT, et al. (2026). A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations.. ESMO open, 11(1), 105932. https://doi.org/10.1016/j.esmoop.2025.105932
MLA Ródon J, et al.. "A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations.." ESMO open, vol. 11, no. 1, 2026, pp. 105932.
PMID 41475241

Abstract

[BACKGROUND] Protein kinase B (AKT)-directed therapies offer promise for patients with cancers harboring germline and somatic phosphatase and tensin homolog (PTEN) mutations. TAS-117 is an oral, selective, non-adenosine triphosphate-competitive allosteric AKT inhibitor that showed encouraging antitumor activity in a phase I study. This phase II study aimed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAS-117 in patients with advanced/metastatic solid tumors, including those harboring germline PTEN-inactivating mutations (EudraCT: 2020-004770-22).

[MATERIALS AND METHODS] In this open-label, multicenter, single-arm phase II study, the 3 + 3 phase I-like dose escalation lead-in part A enrolled patients with advanced/metastatic solid tumors irrespective of gene alterations (all-comers). Patients received TAS-117 once daily (o.d.) or intermittent dosing (ID) regimens (4 days on/3 days off), with a 16-mg/day o.d. or 24-mg/day ID starting dose. The primary objective was safety and to define maximum tolerated dose/recommended phase II dose (RP2D). The dose/regimen confirmation part B was to further assess RP2D in patients harboring germline PTEN mutations.

[RESULTS] Overall, 17 patients were enrolled in part A (all-comers n = 16, dose and regimen confirmation, n = 1). Dose-limiting toxicities were observed in three patients [febrile neutropenia at 20 mg o.d. (n = 1); grade 3 oral mucositis at 28 mg ID (n = 2)]. Most common treatment-related adverse events (AEs) (all grade/grade ≥3) were rash (58.8%/17.6%), fatigue (35.3%/1%), pruritus (29.4%/0%), hyperglycemia (29.4%/1%), and decreased appetite (17.6%/0%). RP2D was determined to be 16 mg/kg o.d. Seven patients had stable disease. One of two patients with a germline PTEN mutation (metaplastic breast cancer) had stable disease ongoing for 19.1 months as of the data cut-off. The study was closed due to enrollment challenges in the germline PTEN mutation carrier population.

[CONCLUSIONS] TAS-117 at the RP2D of 16 mg o.d. was tolerable, with a manageable safety profile. Clinical benefit, although durable, was only observed in a single patient with a germline PTEN mutation.

MeSH Terms

Adult; Aged; Female; Humans; Male; Middle Aged; Antineoplastic Agents; Germ-Line Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Heterocyclic Compounds, 3-Ring

같은 제1저자의 인용 많은 논문 (3)